Immunic posts investor presentation highlighting vidofludimus calcium Phase 3 MS program

Reuters2026/08/11 12:09

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Immunic outlined plans to pivot toward a fully integrated multiple sclerosis focus built around lead oral therapy vidofludimus calcium (IMU-838).
Two Phase 3 relapsing MS trials, ENSURE-1 (N=1,121) and ENSURE-2 (N=1,100), are fully enrolled; top-line data expected by end of 2026.
U.S. NDA submission targeted for mid-2027; potential U.S. regulatory approval projected in 2028.
Phase 2 CALLIPER in progressive MS showed numerical reductions in confirmed disability worsening with signals of disability improvement; Phase 3 program planned later in 2026.
Funding expected into late 2027; U.S. intellectual property protection expected up to 2044.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunic Inc. published the original content used to generate this news brief on August 11, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Immunic posts investor presentation highlighting vidofludimus calcium Phase 3 MS program

You may also like

Crypto prices